From surging hybrid demand to new luxury SUVs outperforming the market, CarGurus data reveals where shoppers are finding the greatest opportunity BOSTON, June 23, 2026 (GLOBE NEWSWIRE) — CarGurus, the No. 1 most visited automotive shopping site in the U.S.1, today released its 2026 Mid-Year Review, highlighting a year shaped so far by resilient consumer demand as consumer preferences are pushing new milestones across key segments, from luxury SUVs selling faster than the new vehicle average to used hybrid prices hitting all-time highs. “The first half of 2026 has been defined by demand holding especially strong at both ends of the price spectrum,” said Kevin Roberts, Director of Economic and Market Intelligence at CarGurus. “At one end, full-size luxury SUVs priced above $80,000 are clearing lots in under 30 days. At the other,...

First Quarter Results Filed: Creatd filed its Quarterly Report for the period ended March 31, 2026, reviewed by the Company’s PCAOB-registered independent auditors, highlighting significant balance sheet developments following the disposition of Flyte. SEC Registration Progress: The Company has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission as part of its initiative to re-establish SEC reporting status. Annual Meeting Update: Creatd has revised the record date for its annual shareholder meeting to Friday, June 26, 2026, and the meeting date to Monday, August 3, 2026. Shareholders of record as of June 26, 2026, will be entitled to vote at the meeting. Shareholder Alignment: Founder and CEO Jeremy Frommer has exchanged certain warrants and Preferred Stock holdings into common stock, simplifying...

SHANGHAI, June 23, 2026 (GLOBE NEWSWIRE) — Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Operational and Financial Highlights:Transaction volume1 was RMB19.3 billion (US$2.8 billion), representing a decrease of 45.8% from the same period of 2025. Average borrowing amount per borrowing was RMB7,111 (US$1,031), representing a decrease of 11.0% from the same period of 2025. Repeat borrowing contribution2 was 76.3%, compared with 71.9% in the same period of 2025. 90 day+ delinquency ratio3 was 2.25% as of March 31, 2026. Net revenue was RMB756.7 million (US$109.7 million), representing a decrease of 57.4% from the same period of 2025. Loss from operation was RMB70.1 million...

23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family Beginnings, reinforcing INVO’s two primary growth avenues SARASOTA, Fla., June 22, 2026 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the first quarter ended March 31, 2026. Q1 2026 Financial Highlights (all metrics compared to Q1 2025 unless otherwise noted)Revenue was $2,015,225, an increase of 23% compared to $1,637,185. Consolidated clinic revenue increased...

Circle8 Acquisition Establishes Global Workforce Solutions Platform Across North America and Europe ENGLEWOOD CLIFFS, N.J., June 22, 2026 (GLOBE NEWSWIRE) — Atlantic International Corp. (Nasdaq: ATLN) today reported financial results for the first quarter ended March 31, 2026, and filed its Quarterly Report on Form 10-Q with the Securities and Exchange Commission. The quarter reflects the first contribution of Circle8 Group following the completion of the acquisition on January 23, 2026. The transaction meaningfully expanded Atlantic’s geographic reach and operating scale, establishing the Company as a transatlantic workforce solutions platform. The quarter also reflects the initial integration of Circle8 and includes acquisition-related accounting and financing impacts associated with the transaction. First Quarter 2026...

HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) — Fervo Energy Company (“Fervo” or the “Company”) (NASDAQ: FRVO), a leading technology-enabled independent power producer of Enhanced Geothermal Systems (EGS), today reported financial and operational results for the first quarter ended March 31, 2026.“This is the geothermal decade, and Fervo is leading the charge,” said Tim Latimer, CEO and Co-founder of Fervo. “2026 is already off to a transformative start. We completed the largest primary energy and power IPO in recent memory, raising $2.2 billion to accelerate our multi-gigawatt development pipeline and near-term execution at Cape Station, the world’s largest enhanced geothermal project, which is on track for first power in Q4 2026. With 658 megawatts of contracted power purchase agreements and a 3-gigawatt geothermal framework agreement...

Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) —  SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced its financial results for the full year ended December 31, 2025. Management Commentary “2025 was a highly transformative and foundational year for SL Science as we aggressively advanced our core cell therapy pipeline and executed our long-term strategic shift toward next-generation immunotherapies. Throughout the past year, we strategically prioritized our resources on high-value clinical research and development, committing over $2.07 million to expand our proprietary cell platforms. This includes advancing our off-the-shelf Gamma Delta T (GDT) cell culture platforms, which is...

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. (“CosmoFarm”), delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million. CosmoFarm added more than 80 new pharmacies to its distribution network during the period, continuing the strong customer growth that has made it one of the leading pharmaceutical wholesalers in the greater Athens area. To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and artificial intelligence systems to enhance procurement, inventory management, and...

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDAResubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the fiscal year ended March 31, 2026. “Since receipt of the U.S. Food and Drug Administration’s (FDA) Complete...

Continued Sales Momentum in National Pharmacy Chains Drives Increase in YOY Revenues and Raises Growth Outlook For 2026GlucoDown® is the first nutritional beverage enriched with our special form of soluble fiber which, clinical data indicates, can reduce your body’s metabolism of dietary sugars. In this way, GlucoDown®’s special soluble fiber helps to moderate increases in blood glucose levels, especially after meals.Bentonville, ARKANSAS, June 18, 2026 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTCID:GLUC), the maker of GlucoDown®, a scientifically formulated blood sugar support beverage, today announced continued growth and increasing momentum within the national pharmacy channel as demand from two of the largest U.S. pharmacy chains strengthened during the second quarter of 2026.  The Company recently...